Baidu's AI Algorithm Shows Early Success in Trials With Stemirna
Baidu and Stemirna Therapeutics have announced successful results of their preclinical trials for a new AI program for sequencing mRNA vaccines.
Grace Lieberman
Grace Lieberman
Oct. 20, 2021 05:12
Baidu's AI Algorithm Shows Early Success in Trials With Stemirna

(CapitalWatch, Oct. 20, New York) AI company Baidu (Nasdaq: BIDU; HKEX: 9888) and mRNA biotechnology company Stemirna Therapeutics recently announced the completion of preclinical studies that characterized the mRNA vaccine sequences for Covid-19 using Baidu's AI algorithm LinearDesign. 

After a year of development and a partnership with Stemirna, a leading company in the field, to test the program, Baidu reports that its new algorithm has proven to have great potential value to the future of mRNA vaccine development. 

The study indicates that the new program outperformed sequences from traditional algorithms in critical aspects of mRNA vaccines including stability, protein expression, and effectiveness. Computer simulations showed that it could take only 11 minutes to use LinearDesign to design an mRNA sequence that could improve the stability and protein expression of an mRNA vaccine candidate.

The study and development of mRNA vaccines has gained explosive attention after the Covid-19 pandemic and the following vaccines, but there are still major obstacles to overcome with this kind of vaccine. Though it's a ground-breaking method for vaccines because of their effectiveness against infectious disease and capability for rapid production, mRNA is unstable and the doses can be difficult to store and distribute.

According to the results of these studies, LinearDesign-based mRNA sequences for Covid-19 vaccine candidates can be stored at warmer temperatures and provide better protection against the virus compared to existing methods. The study found that LinearDesign-based sequences exceeded the benchmarks for key aspects of mRNA vaccines compared to traditional methods, which could lead to significantly higher immune protection. According to Baidu, this technology could also help with research on other infectious diseases, cancer, and rare diseases. 

"With the mission of making the complicated world simpler through technology, Baidu will continue contributions to the global public health cause and building a community with a shared future for humankind," Baidu said in a press release.

Baidu, one of the world's top internet companies, published the LinearDesign in April 2020. Though this algorithm is one of the company's most recent developments, it has been working to advance the computational biology research behind the program since 2018. 

Baidu partnered with Stemirna Therapeutics, the first company in China focused on the research and development of mRNA vaccines and drugs, to test their program and validate its effectiveness. These preclinical trial results show a promising outlook for the new technology.

CapitalWatch Disclaimer

All information contained herein as well as on the CapitalWatch website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of CapitalWatch and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and/or certain risks. This report is not without bias. CapitalWatch received remuneration for this report. Please consult an investment professional before investing in anything viewed within.

Topics :COVID-19 vaccine biotechnology AI;COVID-19, vaccines, biotechnology, AI
Read More

Email: California: 2905 Stender Way #36, Santa Clara, CA 95054 New York: 200 Vesey St Fl 24 New York, NY 10281

Copyright © 2020 JPM Media Corporation, All rights reserved.